Like the Personal Care Products Safety Act in the Senate, a bipartisan discussion draft from New Jersey congressmen Frank Pallone and Leonard Lance would require registration and fees from industry while giving FDA ingredient-review duties and recall authority. 2017 could be the year that cosmetics reform legislation goes the distance, but first the Senate will be holding a related hearing September 22.
Cosmetics reform legislation could have unprecedented momentum behind it going into 2017, following the Sept. 14 release of a discussion draft from House Energy and Commerce members that’s modeled closely after the proposed Personal Care Products Safety Act in the Senate.
Reps. Frank Pallone, D-N.J., and Leonard Lance, R-N.J., aim to introduce the bill during the lame duck session at the...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
